An analysis of the attrition of drug candidates from four major pharmaceutical companies-Reference-Cited by-同舟云学术

An analysis of the attrition of drug candidates from four major pharmaceutical companies

Published:2015-06-19 Issue:7 Volume:14 Page:475-486
ISSN:1474-1776
Container-title:Nature Reviews Drug Discovery
language:en
Short-container-title:Nat Rev Drug Discov

Author:

Waring Michael J.,Arrowsmith John,Leach Andrew R.,Leeson Paul D.,Mandrell Sam,Owen Robert M.,Pairaudeau Garry,Pennie William D.,Pickett Stephen D.,Wang Jibo,Wallace Owen,Weir Alex

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmacology,General Medicine

Link

http://www.nature.com/articles/nrd4609.pdf

Reference26 articles.

1. Hay, M. et al. Clinical development success rates for investigational drugs. Nat. Biotechol. 32, 40–51 (2014).

2. Bunnage, M. Getting pharmaceutical R&D back on target. Nat. Chem. Biol. 7, 335–339 (2011).

3. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–716 (2004).

4. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. Adv. Drug Delivery Rev. 23, 3–25 (1997).

5. Leeson, P. D. & Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6, 881–890 (2007). This paper shows, perhaps for the first time, a link between physicochemical properties, notably lipophilicity and molecular mass, and in vitro promiscuity.

Cited by 1048 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis, docking studies, in silico ADMET predictions, DFT calculations, and photophysical properties of thiazole-anthracene hybrids as potent EGFR inhibitors;Journal of Molecular Structure;2024-12

2. Biopharmaceutical profiling of anti-infective sanggenons from Morus alba root bark for inhalation administration;International Journal of Pharmaceutics: X;2024-12

3. In silico ADMET and DFT analysis of methoxy substituted curcumin derivatives;Inorganic Chemistry Communications;2024-10

4. Analyzing the clinical efficacy and safety of levocetirizine based on its receptor occupancy, intraclass comparison and role in the treatment of CSU: an AROG consensus statement;Expert Review of Clinical Pharmacology;2024-09-12

5. Challenges in validation of combination treatment strategies for CRC using patient-derived organoids;Journal of Experimental & Clinical Cancer Research;2024-09-11